Diabetes. 2020 Sep 16:dbi200032. doi: 10.2337/dbi20-0032. Online ahead of print.
The COVID-19 pandemic has infected over 22.7 million and led to the deaths of 795,000 people worldwide. Diabetes patients are highly susceptible to COVID-19-induced adverse outcomes and complications. The COVID-19 pandemic is superimposing on the preexisting diabetes pandemic to create large and significantly vulnerable COVID-19 diabetes patient populations. This perspective provides an overview of the clinical evidence on the poorer clinical outcomes of COVID-19 infection in diabetes versus non-diabetes patients, including in specific patient populations, such as children, pregnant women, and racial minorities. It also draws parallels between COVID-19 and diabetes pathology, and suggests that preexisting complications or pathologies in diabetes patients might aggravate infection course. Finally, the perspective outlines the prospects for long-term sequelae after COVID-19 for vulnerable diabetes patient populations.